RGDXQ.US Response Genetics Inc

Healthcare Life Sciences Tools & Services USA Stocks
0.0001 USD
Close of Nov 17, 2026
0.0001 0.0001
Market cap
USD 1.37K
P/E
-
P/B
0.00x
ROE
-61.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2015.

Is RGDXQ.US undervalued?

Graham number

The Graham number of Response Genetics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Response Genetics Inc fundamental analysis

No fundamental analysis for Response Genetics Inc yet.

Response Genetics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Response Genetics Inc

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma thro…

Full company profile